Area of research
Physiology · Neurology
Research interest
Research interests include Alzheimer's disease research and treatments, Neurotransmitter Receptor Influence on Behavior, Parkinson's Disease Mechanisms and Treatments, and Amyotrophic Lateral Sclerosis Research.
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Information-Rich, Dual-Function <sup>13</sup>C/<sup>2</sup>H-Isotopic Crosstalk NMR Assay for Human Serine Racemase (hSR) Provides a PLP-Enzyme "Partitioning Fingerprint" and Reveals Disparate Chemotypes for hSR Inhibition.
Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays
Trial of Cinpanemab in Early Parkinson’s Disease
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models